Lidia L Fonseca's Insider Trades & SAST Disclosures
Lidia L Fonseca's most recent trade in Pfizer Inc. was a trade of 156,992 Stock Appreciation Rights done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lidia L Fonseca.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 156,992 | 156,992 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 72,629 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.31 per share. | 27 Feb 2025 | 72,629 | 111,534 (0%) | 0% | 31.3 | 2,274,014 | Common Stock |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.06 per share. | 27 Feb 2025 | 68,022 | 41,829 (0%) | 0% | 26.1 | 1,772,653 | Common Stock |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 27 Feb 2025 | 1,683 | 109,851 (0%) | 0% | 26.1 | 43,926 | Common Stock |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 43,624 | 43,624 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 43,624 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 38,038 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 38,038 | 38,038 | - | - | Stock Appreciation Rights | |
| Medtronic Plc | Lidia L. Fonseca | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 162 | 3,682 (0%) | 0% | 80.9 | 13,104 | Ordinary Shares |
| Medtronic Plc | Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 3,844 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Pfizer Inc. | Fonseca L. Lidia | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 68,045 | 68,045 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | L. Fonseca Lidia | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 60,124 | 60,124 | - | - | Stock Appreciation Rights | |
| TEGNA Inc | Lidia L. Fonseca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 6,039 | 45,221 (0%) | 0% | - | Common Stock | |
| TEGNA Inc | Lidia L. Fonseca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 6,039 | 0 | - | - | Restricted Stock Units | |
| Medtronic Plc | Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,624 | 1,624 (0%) | 0% | 90.7 | 147,264 | Ordinary Shares |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 43,624 | 43,624 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 37,966 | 37,966 | - | - | Stock Appreciation Rights | |
| TEGNA Inc | Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2022 | 5,952 | 5,952 | - | - | Restricted Stock Units | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 38,038 | 38,038 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 33,455 | 33,455 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.69 per share. | 31 Jan 2022 | 6,680 | 34,717 (0%) | 0% | 52.7 | 351,969 | Common Stock |
| TEGNA Inc | Lidia L. Fonseca | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 6,593 | 6,593 | - | - | Restricted Stock Units | |
| TEGNA Inc | Lidia L. Fonseca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 10,410 | 39,182 (0%) | 0% | - | Common Stock | |
| TEGNA Inc | Lidia L. Fonseca | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 10,410 | 0 | - | - | Restricted Stock Units | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 56,888 | 56,888 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 49,153 | 49,153 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Lidia L. Fonseca | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.90 per share. | 31 Jan 2021 | 6,749 | 39,747 (0%) | 0% | 35.9 | 242,289 | Common Stock |
| TEGNA Inc | Lidia L. Fonseca | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 10,204 | 10,204 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges